Cargando…

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No

Detalles Bibliográficos
Autores principales:	Strijbis, EMM, Koch, MW, de Jong, BA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Controversies in Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413779/ https://www.ncbi.nlm.nih.gov/pubmed/37489564 http://dx.doi.org/10.1177/13524585231182708

Ejemplares similares

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes
por: Scalfari, Antonio
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes
por: van Wageningen, Thecla A, et al.
Publicado: (2018)

Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023)

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary
por: Gastaldi, Matteo, et al.
Publicado: (2023)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach – NO
por: Hulst, Hanneke E, et al.
Publicado: (2017)

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022)

Studying the blood–brain barrier will provide new insights into neurodegeneration – Yes
por: Kamphuis, Wouter W, et al.
Publicado: (2018)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No
por: Mühlau, Mark
Publicado: (2022)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – Commentary
por: Hohlfeld, R
Publicado: (2021)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – No
por: McMurran, Christopher E
Publicado: (2021)

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
por: Lycke, Jan, et al.
Publicado: (2022)

All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes
por: Cree, Bruce AC
Publicado: (2022)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

How common is truly benign MS in a UK population?
por: Tallantyre, Emma Clare, et al.
Publicado: (2019)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis
por: Magyari, Melinda, et al.
Publicado: (2022)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Multiple sclerosis risk variants influence the peripheral B‐cell compartment early in life in the general population
por: de Mol, Casper L., et al.
Publicado: (2022)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Higher‐quality diet and non‐consumption of meat are associated with less self‐determined disability progression in people with multiple sclerosis: A longitudinal cohort study
por: Simpson‐Yap, Steve, et al.
Publicado: (2021)

Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study
por: He, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bn82kvtq52c9ae2mvk1rta2phl